Herman Mashaba’s U-turn

‘For smaller schemes, you find that some of them rarely collect contributions in excess of R50 million per year. If they were to fund treatment for one of these diseases, it then becomes a very big portion of what is actually collected,’ says Charlton Murove, head of research at the…

A new proposal to help medical schemes mitigate the cost of ultra-rare disease treatment. Why Mango may have truly reached the end of the runway. And a move to get a uniquely South African crop off the tariff list.

‘We’ve seen almost $165 billion of investment flowing into US-based exchange-traded funds. Much of that could have been invested in emerging markets like South Africa,’ says Marius Reitz, GM for Africa and Europe at Luno.

Exclusions, empty promises and walkouts, why the National Dialogue is being labelled a ‘let down’ by NGOs and activists. Why the Finance Minister’s comments on crypto could see SA fall behind global investment practice. And the role of Japan in driving Africa’s industrialisation, skills development and energy transition.

‘Retaliation, with the scale of market we have, might have other unintended consequences that might potentially be much more counterproductive to our industrial policy ambitions,’ says Ayabonga Cawe, chief commissioner at Itac.